To further understand the impact of oral IMQ or systemic IFNα (with or without topical IMQ) on the antitumor immune response, we analyzed the expression of co-stimulatory/inhibitory molecules (CD80, CD86 and PD-L1) on myeloid cells in the tumor microenvironment, draining lymph node, spleen and small intestine. Here, CD86 is linked to neoplasm.